Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2007 Mar 21

PMID 17370520

Citations 5

Authors

Klaus Dietz

Gunter Raddatz

Jonathan Wallis

Norbert Muller

Inga Zerr

Hans-Peter Duerr

Hans Lefevre

Erhard Seifried

Johannes Lower

Affiliations

Soon will be listed here.

Abstract

Variant Creutzfeldt-Jakob disease (vCJD) may be transmissible by blood. To prevent secondary transmission through blood components, several countries have started to exclude as donors persons who have received a blood transfusion. We investigated the effectiveness of this measure by using a dynamic age-structured model. It is the first such model based on epidemiologic data: 1) blood donor activities, 2) a case-control study on CJD, 3) age distribution of recipients, and 4) death of recipients of blood transfusions. The model predicts that an infection like vCJD, which has been introduced into the population by the alimentary route, could not become endemic by transfusion alone and that only <1% of cases would be avoided by excluding from blood donation those persons who have received a transfusion.

Citing Articles

Engineering Synthetic Erythrocytes as Next-Generation Blood Substitutes.

Gomes F, Jeong S, Shin S, Leijten J, Jonkheijm P Adv Funct Mater. 2024; 34(28).

PMID: 39386164 PMC: 11460667. DOI: 10.1002/adfm.202315879.

Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK.

Garske T, Ghani A PLoS One. 2011; 5(12):e15626.

PMID: 21203419 PMC: 3009744. DOI: 10.1371/journal.pone.0015626.

Preclinical deposition of pathological prion protein in muscle of experimentally infected primates.

Krasemann S, Neumann M, Geissen M, Bodemer W, Kaup F, Schulz-Schaeffer W PLoS One. 2010; 5(11):e13906.

PMID: 21085647 PMC: 2978702. DOI: 10.1371/journal.pone.0013906.

Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated....

Transfus Med Hemother. 2010; 36(1):79-93.

PMID: 21048823 PMC: 2928836. DOI: 10.1159/000188082.

Quality and Safety in Blood Supply in 2010.

Seitz R, Heiden M Transfus Med Hemother. 2010; 37(3):112-117.

PMID: 20577599 PMC: 2889628. DOI: 10.1159/000314497.

References

Collins S, Lawson V, Masters C . Transmissible spongiform encephalopathies. Lancet. 2004; 363(9402):51-61. DOI: 10.1016/S0140-6736(03)15171-9. View

Bacchetti P . Uncertainty due to model choice in variant Creutzfeldt-Jakob disease projections. Stat Med. 2004; 24(1):83-93. DOI: 10.1002/sim.1924. View

Bacchetti P . Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease. Lancet. 2001; 357(9249):3-4. DOI: 10.1016/S0140-6736(00)03559-5. View

Velasco-Hernandez J . A model for Chagas disease involving transmission by vectors and blood transfusion. Theor Popul Biol. 1994; 46(1):1-31. DOI: 10.1006/tpbi.1994.1017. View

Wallis J, Wells A, Matthews J, Chapman C . Long-term survival after blood transfusion: a population based study in the North of England. Transfusion. 2004; 44(7):1025-32. DOI: 10.1111/j.1537-2995.2004.03400.x. View

Zerr I, Brandel J, Masullo C, Wientjens D, De Silva R, Zeidler M . European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J Clin Epidemiol. 2000; 53(7):747-54. DOI: 10.1016/s0895-4356(99)00207-3. View

Peden A, Head M, Ritchie D, Bell J, Ironside J . Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004; 364(9433):527-9. DOI: 10.1016/S0140-6736(04)16811-6. View

Roberts M, Heesterbeek J . A new method for estimating the effort required to control an infectious disease. Proc Biol Sci. 2003; 270(1522):1359-64. PMC: 1691377. DOI: 10.1098/rspb.2003.2339. View

Chadeau-Hyam M, Alperovitch A . Risk of variant Creutzfeldt-Jakob disease in France. Int J Epidemiol. 2005; 34(1):46-52. DOI: 10.1093/ije/dyh374. View

10.

Bacchetti P . Age and variant Creutzfeldt-Jakob disease. Emerg Infect Dis. 2004; 9(12):1611-2. DOI: 10.3201/eid0912.030361. View

11.

Castilla J, Saa P, Soto C . Detection of prions in blood. Nat Med. 2005; 11(9):982-5. DOI: 10.1038/nm1286. View

12.

Inaba H, Sekine H . A mathematical model for Chagas disease with infection-age-dependent infectivity. Math Biosci. 2004; 190(1):39-69. DOI: 10.1016/j.mbs.2004.02.004. View

13.

. Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated.... Transfus Med Hemother. 2010; 36(1):79-93. PMC: 2928836. DOI: 10.1159/000188082. View

14.

Clarke P, Ghani A . Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface. 2006; 2(2):19-31. PMC: 1578257. DOI: 10.1098/rsif.2004.0017. View

15.

Ghani A, Donnelly C, Ferguson N, Anderson R . Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003; 3:4. PMC: 156616. DOI: 10.1186/1471-2334-3-4. View

16.

Valleron A, Boelle P, Will R, Cesbron J . Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science. 2001; 294(5547):1726-8. DOI: 10.1126/science.1066838. View

17.

Llewelyn C, Hewitt P, Knight R, Amar K, Cousens S, Mackenzie J . Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004; 363(9407):417-21. DOI: 10.1016/S0140-6736(04)15486-X. View